Loading...
Loading...
APLS| Name | Value |
|---|---|
| Revenues | 176.6M |
| Cost of Revenue | 33.6M |
| Gross Profit | 143.0M |
| Operating Expense | 210.6M |
| Operating I/L | -67.5M |
| Other Income/Expense | 10.7M |
| Interest Income | 2.9M |
| Pretax | -56.9M |
| Income Tax Expense | 0.6M |
| Net Income/Loss | -57.4M |
Apellis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in developing and commercializing therapeutic compounds that inhibit the complement system for autoimmune and inflammatory diseases. The company's lead product candidate, pegcetacoplan, is in Phase III clinical trials for treating geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria. Additionally, it develops EMPAVELI for various conditions in hematology, nephrology, and neurology. Apellis also works on APL-2006, a bispecific C3 and VEGF inhibitor, and APL-1030, a C3 inhibitor, for complement-mediated disorders. The company generates revenue through the development and commercialization of these therapeutic compounds.
